PharmaGiant.com Expands Access to Affordable Medications; Announces Upcoming Generic Semaglutide
PharmaGiant.com bridges the affordability gap by connecting
Real Savings: Brand Name vs. Canadian Generics
- Rosuvastatin 5mg (30 tablets):
$30 at PharmaGiant vs.$136 U.S. retail. - Amlodipine 5mg (100 tablets):
$58.95 at PharmaGiant vs.$117.14 U.S. retail. - Atorvastatin 10mg (90 tablets):
$24 at PharmaGiant vs.$271 U.S. retail. - Metformin 500mg (100 tablets):
$13.99 at PharmaGiant vs.$33 U.S. retail. - Sertraline 50mg (100 tablets):
$59.99 at PharmaGiant vs.$119 U.S. retail.
Maximize Savings with 90-Day Bulk Orders
PharmaGiant.com encourages patients to utilize 90-day bulk ordering to ensure continuity of care while reducing per-unit costs and shipping expenses. All medications are shipped in temperature-controlled, medical-grade packaging to maintain product integrity.
Limited Time Offer for New Customers
To assist those seeking relief from high pharmacy bills, new customers can use coupon code PGSAVE10 at checkout to receive 10% off their first order.
"Our mission is to ensure no one has to choose between their health and financial stability," said a PharmaGiant.com spokesperson. "The arrival of generic Semaglutide reinforces our commitment to safe, affordable, and transparent healthcare options."
For more information, please visit www.pharmagiant.com.
View original content:https://www.prnewswire.com/news-releases/pharmagiantcom-expands-access-to-affordable-medications-announces-upcoming-generic-semaglutide-302699684.html
SOURCE PharmaGiant.com
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Shiba Inu Price Prediction: SHIB’s Recent 15% Weekly Rally Meets Remittix’s BINANCE500 Campaign
- TSP to Gold IRA Rollover Guide Released for Federal Employees Considering Precious Metals in 2027
- XRP Price Prediction: ETFs Add $38 Million in Two Days as Pepeto 100x Presale Heats Up
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share